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Summary
 
Interleukin (IL)-18 is functionally similar to IL-12 in mediating T helper cell type 1 (Th1) re-
sponse and natural killer (NK) cell activity but is related to IL-1 in protein structure and signal-
ing, including recruitment of IL-1 receptor–associated kinase (IRAK) to the receptor and acti-
 
vation of 
 
c
 
-Jun NH
 
2
 
-terminal kinase (JNK) and nuclear factor (NF)-
 
k
 
B. The role of IRAK in
IL-18–induced responses was studied in IRAK-deficient mice. Significant defects in JNK in-
duction and partial impairment in NF-
 
k
 
B activation were found in IRAK-deficient Th1 cells,
resulting in a dramatic decrease in interferon (IFN)-
 
g
 
 mRNA expression. In vivo Th1 response
to 
 
Propionibacterium acnes 
 
and lipopolysaccharide in IFN-
 
g 
 
production and induction of NK cy-
totoxicity by IL-18 were severely impaired in IRAK-deficient mice. IFN-
 
g
 
 production by ac-
tivated NK cells in an acute murine cytomegalovirus infection was significantly reduced despite
normal induction of NK cytotoxicity. These results demonstrate that IRAK plays an important
role in IL-18–induced signaling and function.
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I
 
nterleukin (IL)-18 (previously known as IFN-
 
g
 
–inducing
factor, or IGIF) was cloned from the liver of mice primed
 
with 
 
Propionibacterium acnes
 
, followed by challenge with LPS
(1). IL-18 induces production of IFN-
 
g
 
 from Th1 cells and
NK cells (2–5). In addition, IL-18 enhances NK cell cy-
totoxicity and also synergizes with IL-12 in potentiating
IFN-
 
g
 
 production and NK cell cytotoxicity (1, 3, 4). Thus,
cellular responses to IL-18 are similar to the biological func-
tions known to be elicited by IL-12 (6).
Despite functional similarities, IL-12 and IL-18 differ in
their protein structure and exert these overlapping and syn-
ergistic biological effects via different mechanisms. IL-12
 
mediates Th1 responses and IFN-
 
g
 
 production via activation
 
of Janus kinases (JAKs),
 
1
 
 JAK2 and TYK2 (7), and transcrip-
tion factors called signal transducer and activator of tran-
scription (STAT), STAT3 and STAT4 (8). STAT4-defi-
cient mice are defective in mounting Th1 responses and
IFN-
 
g
 
 production (9, 10). Stimulation with IL-18 results
in activation of 
 
c
 
-Jun NH
 
2
 
-terminal kinase (JNK) and tran-
scription factor nuclear factor (NF)-
 
k
 
B (2, 4).
IL-18 is similar in tertiary structure to proteins of the IL-1
family (11). Similar to IL-1
 
b
 
, IL-18 is synthesized as an in-
active precursor protein and is cleaved to the active form
by IL-1
 
b
 
–converting enzyme (ICE, also named caspase 1;
references 12, 13). Cleavage of IL-18 by ICE is essential for
the biological effects of IL-18. ICE-deficient mice exhibit
 
defects similar to those observed in IL-18
 
2
 
/
 
2
 
 mice, such as
reduced IFN-
 
g
 
 production in response to LPS injection (3,
12, 13). The IL-18 receptor was originally identified as IL-1
receptor–related protein (IL-1Rrp; references 14, 15). Re-
ceptors for IL-1, IL-18, and the recently identified mam-
malian Toll-like receptors (16) are evolutionarily conserved
and homologous to the 
 
Drosophila
 
 protein Toll (17). Toll
mediates activation of Dorsal, an NF-
 
k
 
B–like molecule, via
the serine threonine kinase Pelle and the adapter protein
Tube (17, 18). The IL-1 signaling pathway in mammals is
similar to the Toll pathway. NF-
 
k
 
B activation by IL-1 re-
 
1
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Role of IRAK in IL-18–induced Signaling and Function
 
quires the interaction of the Pelle-like kinase IL-1 receptor–
associated kinase (IRAK) with the IL-1 receptor complex
via the adapter protein MyD88 (19–21). IL-18 also triggers
phosphorylation of IRAK and its recruitment to the IL-18
receptor complex (4, 22). However, IL-1 and IL-18 act on
different cell types and lead to divergent cellular responses.
For example, IL-18 has been implicated primarily in induc-
ing IFN-
 
g
 
 from NK and Th1 cells (1–5), whereas IL-1 is a
potent inducer of IL-6 from fibroblasts and macrophages dur-
ing inflammation (23–25). We have recently demonstrated
that IRAK is required for optimal induction of IL-1 signal-
ing, including JNK, p38, and NF-
 
k
 
B activation (25). Defec-
tive IL-1 signaling in IRAK-deficient fibroblasts results in
impaired IL-6 induction (25). Although IL-18 signaling is
known to involve activation of JNK and NF-
 
k
 
B (2, 4),
details of IL-18 signaling have not been well characterized.
It is also unclear whether IL-18 uses IRAK in pathways
similar to IL-1 signaling to elicit distinct cellular responses.
To determine the role of IRAK in IL-18–mediated re-
sponses, we analyzed IL-18–induced signaling and function
in IRAK-deficient mice.
In this report we showed that IRAK was essential for
IL-18–mediated activation of JNK and was also involved in
NF-
 
k
 
B activation. Signaling defects in IRAK-deficient
Th1 cells resulted in a dramatic decrease in IFN-
 
g
 
 expres-
sion. Serum IFN-
 
g 
 
increase in response to 
 
P. acnes
 
 and LPS
treatment was severely impaired. IRAK-deficient mice also
exhibited defects in NK IFN-
 
g
 
 production in an acute mu-
rine cytomegalovirus (MCMV) infection. NK cell cytotox-
icity induced by IL-18 was defective, although its induc-
tion was normal in MCMV infection. These results suggest
that IRAK plays an important role in IL-18–mediated sig-
naling and function.
 
Materials and Methods
 
Generation of IRAK-deficient Mice.
 
The mouse IRAK gene in
embryonic stem (ES) cells was disrupted by homologous recom-
bination as described in our previous report (25). In brief, the
mouse IRAK gene was disrupted by replacement of a 940-bp re-
gion covering exons 5–7 of the gene with a neomycin resistance
gene. Chimeric mice were generated from embryos injected with
ES cells. Germline mice were obtained from breeding of chimeric
male mice with C57BL/6J females. Because the IRAK gene is on
X chromosome (sequence data available from EMBL/GenBank/
DDBJ under accession No. U52112) and the ES cell line was de-
rived from a male embryo, all the germline female mice were
heterozygous for the disrupted IRAK gene. IRAK-deficient male
mice carrying only the disrupted IRAK gene were obtained from
breeding of heterozygous female mice with wild-type littermates.
IRAK-deficient female mice were obtained from breeding of
heterozygous females with IRAK-deficient males.
 
Phenotypic Analysis of T Cells.
 
Thymocytes and splenocytes
were stained with CD4- and CD8-specific antibodies (PharMin-
gen). Enriched CD4
 
1
 
 T cells before and after 5 d of differentia-
tion were stained with antibodies specific for CD25 and CD44
(PharMingen). Cells after antibody staining were analyzed using a
FACScan™ (Becton Dickinson).
 
Preparation of Th1/Th2 Cells.
 
CD4
 
1
 
 T cells were purified
from lymph node and spleen cells by depletion of B cells and
 
CD8
 
1
 
 T cells using guinea pig and rabbit complements and a
combination of antibodies from hybridoma lines J11d, 28-16-8s,
and 3-168. Purity of CD4
 
1
 
 T cells in different preparations was
 
z
 
90%. Enriched CD4
 
1
 
 T cells were activated with immobilized
anti-CD3 (PharMingen), which was coated overnight onto 6-well
plates at 5 
 
m
 
g/ml. Differentiation of T cells towards Th1 cells was
triggered by addition of 5 ng/ml IL-12 (R&D Systems) and 5 
 
m
 
g/ml
anti–IL-4 (PharMingen) in RPMI medium with 10% FCS. Th2
cell differentiation was driven by supplementing culture medium
with 5 ng/ml IL-4 (R&D Systems) and 5 
 
m
 
g/ml of anti–IFN-
 
g
 
plus anti–IL-12 (PharMingen). The cytokine profile of Th1 or
Th2 cells was determined by plating the cells at 2 
 
3 
 
10
 
5
 
 cell/well
in 96-well plates that were precoated overnight with 5 
 
m
 
g/ml
anti-CD3. Culture supernatants were collected 24 h later for cyto-
kine detection by ELISA.
 
Cell Stimulation.
 
After 5 d of differentiation, Th1 cells were
washed once with serum-free RPMI medium and starved for 3 h
before stimulation. Cells were treated with different stimuli at
37
 
8
 
C. The different stimuli used in the assays include: IL-18 (Pep-
roTech, Inc.), IL-12 (R&D Systems); IL-1
 
b
 
 (R&D Systems);
TNF-
 
a
 
 (Genzyme Corp.); PMA and ionomycin (Sigma Chem-
ical Co.). After stimulation, cells were lysed for 20 min at 4
 
8
 
C with
lysis buffer (100 
 
m
 
l/5 
 
3 
 
10
 
6
 
 cells) containing 10 mM Hepes, pH
7.5, 150 mM NaCl, 1% NP-40, 1 mM Na
 
3
 
VO
 
4
 
,
 
 
 
10% glycerol,
1 
 
m
 
g/ml leupeptin, 1 
 
m
 
g/ml aprotinin, 1 mM PMSF, and 1
mM EDTA. Cell lysates for kinase assays and Western blots were
collected after centrifugation of samples at 14,000 rpm for 10 min
at 4
 
8
 
C.
 
In Vitro Kinase Assay.
 
Cell lysates (5 
 
3 
 
10
 
6
 
 cells in 100 
 
m
 
l of
lysis buffer) were immunoprecipitated with JNK1 kinase antibody
(Santa Cruz Biotechnology). An in vitro kinase assay was per-
formed using glutathione 
 
S
 
-transferase (GST)–
 
c
 
-Jun (Santa Cruz
Biotechnology) as a substrate in a reaction buffer containing 25
mM Hepes, pH 7.4, 25 
 
m
 
M ATP, 10 mM MgCl
 
2
 
, 1 
 
m
 
g GST–
 
c
 
-Jun, and 10 
 
m
 
Ci [
 
g
 
-
 
32
 
P]ATP for 30 min at 37
 
8
 
C. Samples after
kinase assays were separated on 10% SDS-PAGE, transferred to
nitrocellulose filters (MSI), and then subjected to autoradiogra-
phy. Radioactivity of the phosphorylated 
 
c
 
-Jun bands were quan-
titated by PhosphorImager (Molecular Dynamics Inc.). JNK1
protein on blotted filters was detected with a JNK1-specific anti-
body (Santa Cruz Biotechnology).
 
Western Blotting.
 
Western blot analyses were carried out as
previously described (26). For detection of I
 
k
 
B-
 
a
 
 protein levels,
cell lysates (10
 
5
 
 cells/sample) were separated on 10% SDS-PAGE
(Novex) and transferred to nitrocellulose filters. Filters were im-
munoblotted with an I
 
k
 
B-
 
a
 
–specific rabbit antibody (Santa Cruz
Biotechnology) and detected with horseradish peroxidase–conju-
gated rabbit IgG and enhanced chemiluminescence (Amersham
Pharmacia Biotech). Filters were then stripped by soaking in 0.1 M
glycine/HCl, pH 2.6, for 30 min and reprobed with an ERK-2–
specific antibody (Santa Cruz Biotechnology) for normalization.
 
NF-
 
kB Mobility Shift Assay. Cells after treatment with differ-
ent stimuli were pelleted and taken up in 500 ml ice-cold buffer
A (10 mM Hepes, pH 7.9, 10 mM KCl, 100 mM EDTA, 100 mM
EGTA, 1 mM dithiothreitol, 500 mM PMSF) and kept on ice for
15 min. Samples were then added with 30 ml of 10% NP-40 fol-
lowed by centrifugation at 14,000 rpm for 30 s. Nuclear pellets
were washed once with buffer A and lysed in 50 ml buffer B
(20 mM Hepes, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM dithiothreitol, 1 mM PMSF) for 30 min at 48C.
Nuclear extracts were collected after centrifugation of the samples
at 14,000 rpm for 10 min. Protein concentration was determined
by the BCA method (Pierce Chemical Co.). The consensus double-1131 Kanakaraj et al.
stranded oligonucleotide for NF-kB binding (Santa Cruz Biotech-
nology) was labeled using [g-32P]ATP and T4 polynucleotide ki-
nase. Nuclear binding reactions were carried out for 30 min at
room temperature in a 20 ml mixture containing 10 mg nuclear
extract and 0.5 ng 32P-labeled oligonucleotide probe (100,000
cpm) in buffer C (5 mM Hepes, pH 7.9, 5 mM MgCl2, 1 mM
EDTA, 10% glycerol, and 1 mg/ml poly[dI-dC]). Oligonucleo-
tide–protein complexes were separated on 6% polyacrylamide/
0.53 TBE gels and detected by autoradiography.
Northern Blot Analysis. Total RNA was extracted from cells
or spleens with RNAzol (Tel-Test Inc.). RNA was separated on
1% agarose-formaldehyde gels and transferred to nylon membranes
(Amersham Pharmacia Biotech). Filters were hybridized to cDNA
probes specific for IFN-g (Clontech) and IL-18 (Research Gene-
tics, Inc.). cDNA probes were labeled with a-[32P]dCTP (Amer-
sham Pharmacia Biotech) by random priming (Boehringer Mann-
heim). Radioactive signals were detected by autoradiography.
Filters were then stripped by boiling in 0.1% SDS and rehybridized
with glycerol-3-phosphate dehydrogenase cDNA probe (Clontech)
for normalization.
Cytokine Detection. IFN-g and IL-4 in serum samples and
culture supernatants were determined by using commercially
available ELISA kits (Genzyme) and recombinant cytokines were
used as standards provided by the manufacturer.
Cell Proliferation Assay. Th1 cells were plated in 96-well
plates at 105/well and treated with different cytokines for 24 h.
[3H]thymidine (1 mCi/well) was then added for 16 h, and radio-
activity incorporated in dividing cells was measured using a Top-
count Microplate Scintillation Counter (Packard).
In Vivo Th1 Response. Mice were injected intraperitoneally
with PBS as controls or PBS with 2 mg of heat-killed P. acnes
(Van Kempen Group, Inc.). 7 d later, control mice were injected
intravenously with PBS, whereas P. acnes–primed mice were in-
jected with 1 mg LPS (Sigma Chemical Co.). Mice were bled 6 h
after LPS challenge, and serum IFN-g levels were measured by
ELISA (Genzyme). Total RNA was extracted from spleen sam-
ples for Northern blot analysis.
NK Cytotoxic Assay. Mice were injected intraperitoneally
daily with PBS alone as controls or PBS containing 1 mg IL-18 or
200 mg poly(I):poly(C) (Sigma Chemical Co.) for 2 d. Spleen
cells prepared from these mice were incubated with 51Cr-labeled
YAC-1 target cells for 4 h at 378C at different E/T ratios. After 4 h
of incubation, 51Cr released from target cells was counted using a
gamma counter (Packard). Specific lysis was calculated as: (measured
51Cr release 2 spontaneous 51Cr release)/(maximum 51Cr release 2
spontaneous 51Cr release) 3 100. Maximum release was obtained
by counting acid-lysed target cells. Spontaneous release was ob-
tained by incubating target cells in the absence of effector cells.
MCMV Infections. The Smith strain of MCMV was obtained
from the American Type Culture Collection (VR-1399). MCMV
stocks were prepared in NIH 3T3 murine fibroblasts, and deter-
mination of viral titers was carried out by a standard plaque assay
(27). Mice were intraperitoneally injected with 108 PFU of tissue
culture–propagated MCMV in 400 ml DMEM. Animals were
killed on day 3 after inoculation. Blood sera for cytokine detec-
tion were collected by bleeding mice daily starting from day 0
before viral inoculation. Spleens were collected after 71 h of in-
fection for NK cytotoxic assays and RNA extraction.
Results
Normal Differentiation of Th1 and Th2 Cells in the Absence
of IRAK. IL-18 by itself has no effect on Th1 differentia-
tion but can synergize IL-12–driven Th1 development (4).
In differentiated helper T cells, IL-18 exerts its biological
effects only on Th1 cells but not on Th2 cells (4). Since
IRAK is involved in IL-18 signaling (4, 22), we examined
helper T cell development and phenotype in IRAK-defi-
cient mice. Development of T cells in the thymus and distri-
bution of mature CD41 and CD81 T cells in the primary
and secondary lymphoid organs of IRAK-deficient mice ap-
peared to be normal (Fig. 1 A). The vast majority of CD41
T cells were characterized as CD25loCD44lo naive pheno-
type and were comparable to the cells harvested from control
wild-type mice (Fig. 1 B). Th1 and Th2 cells were prepared
by in vitro differentiation of CD41 T cells from IRAK-defi-
cient and wild-type mice. CD41 T cells were enriched from
lymph node cells and splenocytes by antibody and comple-
ment depletion as described in Material and Methods. En-
riched CD41 T cells were activated with immobilized anti-
CD3 and differentiation towards Th1 cells was triggered by
coculture with IL-12 and anti–IL-4. Th2 cell differentia-
tion was driven by IL-4 and anti–IFN-g plus anti–IL-12.
Activation of IRAK-deficient CD41 T cells appeared to be
normal, as indicated by the upregulation of the activation
marker CD25 and the memory T cell marker CD44 (Fig.
1 B). Numbers of blasting T cells after 5 d of differentiation
were similar between IRAK-deficient and wild-type T cells
(data not shown), suggesting normal proliferation of acti-
vated IRAK-deficient T cells. Cytokines expressed by T cells
after 5 d of differentiation were characterized by ELISA.
Similar to wild-type Th1 cells, IRAK-deficient Th1 cells se-
creted predominantly IFN-g, whereas IL-4 was undetect-
able (Fig. 1 C). IRAK-deficient Th2 cells also showed a
typical Th2 cytokine profile similar to that of wild-type
Th2 cells, with high amounts of IL-4 but minimal levels of
IFN-g (Fig. 1 C). Our data suggest that IRAK-deficient T
cells can differentiate into Th1 or Th2 effector cells.
Impaired JNK Activation by IL-18 in IRAK-deficient Cells.
The stress-activated protein kinase (SAPK) family of mito-
gen-activated protein (MAP) kinases JNK and p38 are rap-
idly activated by proinflammatory cytokines such as IL-1 and
TNF-a (24, 25, 28). IL-18 stimulation of Th1 cells also re-
sults in JNK activation (2). JNK plays a role in induction of
activator protein (AP)-1–dependent genes via phosphoryla-
tion of the transcription factor c-Jun (28, 29). We have shown
previously that IRAK-deficient fibroblasts are defective in
IL-1–mediated JNK activation (25). To determine the role of
IRAK in IL-18–induced JNK activation, JNK activity in Th1
cells was studied by immunoprecipitating JNK1 with a spe-
cific antibody followed by an in vitro kinase assay using the
GST–c-Jun protein as a substrate. Activation of JNK was
minimal in IL-18–treated IRAK-deficient Th1 cells as op-
posed to the significant JNK activation observed in wild-type
cells (Fig. 2). In contrast, TNF-a induced similar levels of
JNK activity in both wild-type and IRAK-deficient Th1
cells, whereas IL-1b did not have any effects on either sam-
ples (Fig. 2). IL-18 and IL-1 have been suggested to act on
Th1 and Th2 cells, respectively, to induce signaling and
cellular responses (4). In our studies, Th1 cells do not respond
to IL-1b in JNK activation and this is consistent with a previ-1132 Role of IRAK in IL-18–induced Signaling and Function
ous observation (4), which suggested that IL-1 does not in-
duce signaling in Th1 cells due to the lack of IL-1 receptor
expression. Our results indicate that the defect in JNK activa-
tion observed in IRAK-deficient Th1 cells is IL-18 specific.
IRAK Is Dispensable for NF-kB Activation by IL-18. IL-18
binding to its receptor mediates activation of NF-kB (4, 22).
In unstimulated cells, NF-kB is present in the cytoplasm as
an inactive complex sequestered by its inhibitory partners,
IkB (30). Upon activation, IkB proteins are phosphorylated
by IkB kinases IKK1 and IKK2, and subsequently degraded
by proteosomes to allow nuclear translocation and activa-
tion of NF-kB (30–32). To determine the role of IRAK
in IL-18–induced NF-kB activation, IkB-a protein levels
were determined in Th1 cells stimulated with IL-18 for
different time courses (Fig. 3 A). Reduced levels of IkB-a
due to protein degradation were observed in both wild-
type and IRAK-deficient cells after IL-18 treatment (Fig.
3 A). Maximum degradation of IkB protein occurred 15 min
after stimulation and returned to 80% of original levels within
60 min of stimulation. The extent of IkB-a protein degra-
dation mediated by IL-18 appeared to be less in IRAK-defi-
cient Th1 cells as compared with that in wild-type cells.
Similar results were observed when wild-type and IRAK-
deficient Th1 cells were stimulated with different concen-
trations of IL-18 (data not shown). This result was further
confirmed by NF-kB DNA binding activity in nuclear
extracts determined by mobility shift assay. IL-18–induced
NF-kB activation in both IRAK-deficient and wild-type
cells, but NF-kB DNA binding activity was slightly lower
in IRAK-deficient cells than in wild-type cells (Fig. 3 B).
Stimulation with TNF-a or phorbol ester plus ionomycin
induced comparable levels of NF-kB activation in both cell
types, indicating that the partial defect in NF-kB activation
observed in IRAK-deficient cells is restricted to IL-18 stim-
ulation. These results suggest that involvement of IRAK in
IL-18–mediated NF-kB activation is dispensable.
IRAK Is Required for IL-18–induced IFN-g Production.
IL-18 induces IFN-g production from Th1 cells (1, 5).
Figure 1. IRAK is dispensable for T cell development and Th1/Th2 differen-
tiation. (A) CD41 and CD81 T cell populations in the thymuses and the spleens
of IRAK-deficient [IRAK(2)] and wild-type mice were analyzed in flow cy-
tometry. Immature CD41 CD81 double positive T cells in thymuses are also
shown. (B) CD41 T cells purified from the spleens and lymph nodes of IRAK-
deficient [IRAK(2)] and wild-type mice were stimulated in anti-CD3 coated
plates in the presence of IL-12 and anti–IL-4 for Th1 differentiation or IL-4 and
anti–IFN-g plus anti–IL-12 for Th2 differentiation. Enriched CD41 T cells be-
fore (broken line) and after (solid line) 5 d of stimulation were stained with anti-
bodies specific for CD25 and CD44 for flow cytometry analysis. (C) After 5 d of
Th1 or Th2 differentiation, cells were washed and restimulated overnight with
anti-CD3 antibody. IFN-g and IL-4 levels in culture supernatants were deter-
mined by ELISA.
Figure 2. Impaired IL-18–mediated JNK activation in IRAK-deficient
Th1 cells. IRAK-deficient [IRAK(2)] and wild-type Th1 cells were
stimulated with medium alone, IL-1b (10 ng/ml), TNF-a (50 ng/ml), or
different concentrations of IL-18 as indicated for 15 min. Cell lysates
were immunoprecipitated with a JNK-specific antibody. In vitro JNK ki-
nase assay was performed using GST–c-Jun as a substrate. Amounts of
JNK protein in the immune complexes were detected by Western blot-
ting using a JNK-specific antibody.1133 Kanakaraj et al.
Stimulation of Th1 cells with a combination of IL-18 and
IL-12 results in synergistic induction of IFN-g production
(4). To determine whether IRAK is required for induction
of IFN-g by IL-18 itself or in combination with IL-12,
IFN-g mRNA expression was determined by Northern
blot analysis. IFN-g was significantly induced by IL-18 in
wild-type cells but its induction in IRAK-deficient cells
was minimal (Fig. 4 A). A suboptimal dose of IL-12 was
used in our experiments, which induced minimal amounts
of IFN-g, and no difference was observed between IRAK-
deficient and wild-type cells. Synergistic induction of IFN-g
expression by a combination of IL-18 and IL-12 was sub-
stantially decreased in IRAK-deficient cells as compared with
wild-type cells. This result shows that IRAK is required for
optimal induction of IFN-g by IL-18.
It has been demonstrated that treatment with LPS in
P. acnes–sensitized mice results in a significant increase in
serum IFN-g (33). IL-18–deficient mice exhibited a mini-
mal increase in serum IFN-g under these conditions (3). To
determine the role of IRAK in IL-18–dependent IFN-g
production in vivo, IRAK-deficient mice were tested in
this experimental system. Mice were injected intraperitoneally
with heat-killed P. acnes and 7 d later were injected intra-
venously with LPS. IFN-g in the serum was detected by
ELISA 6 h after LPS treatment. Serum IFN-g levels were
significantly lower in IRAK-deficient mice as compared with
wild-type animals (Fig. 4 B). Consistent with these data,
IFN-g mRNA expression in the spleen was substantially
reduced in IRAK-deficient mice. In contrast, induction of
IL-18 mRNA expression was comparable between wild-
type and IRAK-deficient animals (Fig. 4 C). These results
suggest that the reduced IFN-g production in IRAK-defi-
cient mice is not due to a change in IL-18 levels but rather
originated from defects in IL-18 signaling.
Decreased Proliferation of IRAK-deficient Th1 Cells. Similar
to induction in IFN-g production, proliferation of Th1
cells was also enhanced by IL-18 or IL-12, and synergized
by the combination of both (4). The effect of IL-18 and its
synergism with IL-12 on proliferation of IRAK-deficient
Th1 cells was studied. Wild-type and IRAK-deficient Th1
cells were treated with different concentrations of IL-18,
IL-12, or IL-18 plus IL-12. Proliferation of Th1 cells after
24 h of stimulation was determined by [3H]thymidine up-
Figure 3. Reduced NF-kB activation by IL-18 in IRAK-deficient
Th1 cells. (A) Reduced degradation of IkB-a in IRAK-deficient cells.
IRAK-deficient [IRAK(2)] and wild-type cells were stimulated with IL-18
(50 ng/ml) for different time courses as indicated. Cell lysates were pre-
pared and separated on SDS-PAGE. IkB-a was detected by Western blot
analysis using an IkB-a–specific antibody. Amounts of protein loading
were determined by probing the same filter with antibody specific for
ERK-2. (B) Reduced NF-kB activation by IL-18 in IRAK-deficient
cells. Cells were stimulated with IL-18 (50 ng/ml), TNF-a (50 ng/ml),
or PMA (50 ng/ml) plus ionomycin (0.125 mM) for 30 min. Nuclear ex-
tracts were prepared and incubated with 32P-labeled NF-kB specific dou-
ble-stranded oligonucleotide. The NF-kB DNA complex was separated
on 6% polyacrylamide gel in 0.5% Tris-borate-EDTA.
Figure 4. Defective induction of IFN-g production in IRAK-deficient mice. (A) Defective IFN-g mRNA expression induced by IL-18 in IRAK-defi-
cient Th1 cells. IRAK-deficient [IRAK(2)] and wild-type Th1 cells were stimulated with IL-18 (50 ng/ml), IL-12 (10 ng/ml), or a combination of
IL-18 and IL-12 for 2 h. Total RNA was prepared from the cells and IFN-g expression was determined by Northern blot analysis using 32P-labeled IFN-g
cDNA probe. The blots were stripped and hybridized to glycerol-3-phosphate dehydrogenase (G3PDH) cDNA for normalization. (B) Reduced induc-
tion of IFN-g production in P. acnes–primed and LPS-challenged IRAK-deficient mice. IRAK-deficient [IRAK(2)] and wild-type mice were intraperi-
toneally injected with 2 mg of heat-killed P. acnes. Mice were intravenously injected with 1 mg LPS on day 7. Serum samples were collected 6 h after
LPS challenge and levels of IFN-g in sera were determined by ELISA. (C) Total spleen RNA was prepared from P. acnes– and LPS–treated mice. IFN-g
expression was determined by Northern blot hybridization using 32P-labeled IFN-g cDNA probe. The blot was stripped and hybridized with IL-18
cDNA probe.1134 Role of IRAK in IL-18–induced Signaling and Function
take. As shown in Fig. 5, proliferation of wild-type Th1
cells was significantly enhanced by IL-18 in a dose-depen-
dent manner, whereas the effect of IL-18 on proliferation
of IRAK-deficient cells was minimal. At concentrations as
low as 2 ng/ml, IL-12 stimulated proliferation of both wild-
type and IRAK-deficient cells to maximal extent. Combina-
tion of IL-18 and IL-12 resulted in a synergistic proliferative
response in both cell types, and no significant difference
was observed. Consistent with the defects shown in IFN-g
expression, IRAK-deficient cells are also impaired in pro-
liferative response to IL-18, confirming the role of IRAK
in IL-18–mediated cellular responses.
Defective Induction of NK Cell Activity by IL-18 in IRAK-defi-
cient Mice. IL-18 has been shown to enhance NK cell cyto-
toxicity (1). Reduced NK activity was reported in IL-18–
deficient mice (3). To determine whether IRAK is involved
in IL-18–induced NK activity, mice were injected intraperi-
toneally with IL-18 for 2 d consecutively, and NK activity in
splenocytes was assayed using 51Cr-labeled YAC-1 as target
cells. Basal NK cell activities in PBS injected wild-type and
IRAK-deficient mice were comparable (Fig. 6). IL-18 in-
jection resulted in significant increase in NK activity in
wild-type animals but its effect in IRAK-deficient mice was
minimal (Fig. 6). However, injection of the double-stranded
RNA poly(I):poly(C), an inducer of IFNs, resulted in a
pronounced NK activity in both IRAK-deficient and wild-
type animals (Fig. 6), indicating that IRAK is required spe-
cifically for IL-18–mediated induction of NK cytotoxic ac-
tivity.
IRAK Is Essential for MCMV-induced IFN-g Production but
Not for NK Cell Cytotoxicity. NK cells are the major effector
cells in the early defense against viral infections. Both NK
cytotoxicity and IFN-g production by NK cells are in-
duced in mice upon MCMV infection (34). IL-12 has been
shown to be responsible for induction of IFN-g in NK cells
(35), whereas possible roles of IL-18 in NK activities dur-
ing MCMV infection have not been reported. IRAK-defi-
cient mice were infected with MCMV to study the in-
volvement of IRAK in NK activity during viral infection.
Splenocytes obtained from mice on day 3 of MCMV in-
fection were assayed for NK cytolytic activity using 51Cr-
labeled YAC-1 cells as targets. Dramatic increase in NK cy-
totoxicity was observed in both MCMV-infected wild-type
and IRAK-deficient mice and no significant difference was
found between the two types of mice (Fig. 7 A). IFN-g
produced by NK cells during MCMV infection can be de-
tected as an increase in serum IFN-g levels. Kinetics of
IFN-g increase in sera during the first 3 d of MCMV infec-
tions was studied. In both wild-type and IRAK-deficient
mice, IFN-g levels peaked at 45 h of infection (Fig. 7 B).
However, maximal IFN-g levels in IRAK-deficient mice
were significantly lower than those in wild-type control
mice (Fig. 7 B). Similar results were obtained in studies of
IFN-g mRNA expression. IFN-g mRNA in the spleens
was undetectable in uninfected mice but was induced signif-
icantly in MCMV infected mice (Fig. 7 C). IFN-g mRNA
Figure 5. Defective IL-18–induced proliferation of IRAK-deficient
Th1 cells. Th1 cells (105 cells /well) were plated on a 96-well plate and
cultured in RPMI medium with the indicated concentrations of IL-18,
IL-12, or IL-18 plus IL-12 for 24 h. Cell proliferation was determined by
[3H]thymidine incorporation.
Figure 6. Impaired IL-18–induced NK cytotoxicity in IRAK-deficient
mice. IRAK-deficient [IRAK(2)] and wild-type mice were injected in-
traperitoneally with PBS, 1 mg IL-18, or 200 mg poly(I):poly(C) for 2 d
consecutively. Spleen cells were assayed for NK cytotoxic activity against
51Cr-labeled YAC-1 target cells.1135 Kanakaraj et al.
induced by MCMV was less significant in IRAK-deficient
mice than that in wild-type mice. IL-18 expression in re-
sponse to MCMV infection was also studied. IL-18 mRNA
was expressed at low levels in the spleens of uninfected
mice and was induced strongly on day 3 of MCMV infec-
tion (Fig. 7 C). IL-18 expression in IRAK-deficient mice
was comparable to that in wild-type mice under healthy
and viral-infected conditions (Fig. 7 C). Thus, impairment in
viral-induced IFN-g production in IRAK-deficient mice is
not due to the levels of IL-18 expression, suggesting that
other mechanisms, such as IL-18 signaling, may be respon-
sible for the defects.
Discussion
Role of IRAK in IL-18 Signaling Pathways. We have dem-
onstrated IL-18 signaling defects in IRAK-deficient Th1
cells. Impairment is significant in JNK activation but much
less obvious in NF-kB induction. The partial activation of
NF-kB suggests that other mechanisms can compensate
for the function of IRAK. However, the role of IRAK in
JNK activation is essential. We have previously reported
that IRAK-deficient fibroblasts are defective in both NF-kB
and JNK/p38 pathways induced by IL-1 (25). The defects
in IL-18 signaling that we observed here are similar to the
defects in IL-1 signaling (25). Impairment in NF-kB acti-
vation can be overcome by high concentrations of IL-1, but
similar treatment cannot correct defects in JNK activation
(25). Taken together, our results suggest that IRAK is used
similarly by both IL-18 and IL-1 in mediating intracellular
signaling.
IL-1 signaling leading to NF-kB activation has been rel-
atively well characterized. Upon IL-1 binding to its recep-
tor, IRAK is rapidly recruited to the receptor complex via
MyD88 (20). Activated IRAK interacts with TNF recep-
tor–associated factor (TRAF)6, which in turn activates
NF-kB–inducing kinase (NIK) (36, 37). NIK is involved
in the NF-kB pathway by activating IkB kinases (IKKs)
(31, 32, 38, 39). Activated IKKs phosphorylate IkB for deg-
radation, allowing nuclear translocation of NF-kB for gene
induction (30). However, details of IL-1–mediated signal-
ing leading to JNK activation are still unclear. It has been
reported that only MyD88 but not TRAF6 is essential for
JNK activation (40). Since IRAK is positioned between
MyD88 and TRAF6 in the signaling cascade, IRAK could
be the bifurcating molecule for both NF-kB and JNK
pathways. IL-18 stimulation also induces the stress-acti-
vated MAP kinase JNK (2). The defects in JNK activation
in IRAK-deficient cells indicate that IRAK is essential for
JNK activation but intermediary molecules linking IRAK
to JNK have not been identified.
Recent reports on IL-1 signaling also suggest additional
complexity and divergence in this pathway. In addition to
IRAK, other proteins, including IRAK homologue IRAK2,
are reported to interact with the IL-1 receptor (19, 41).
IRAK2 also interacts with MyD88 and TRAF6 (19). A
dominant negative form of IRAK2 mutant blocks MyD88-
induced NF-kB activation (19). Although overexpression of
IRAK in transfection studies has been reported to activate
NF-kB but not JNK (42), our studies demonstrate that
IRAK is essential for IL-18–mediated activation of JNK
but its role in NF-kB pathway is less critical. In the absence
Figure 7. Reduced MCMV-induced IFN-g production but normal NK cell cytotoxicity in IRAK-deficient mice. IRAK-deficient [IRAK(2)] and
wild-type mice were injected intraperitoneally with 108 PFU of MCMV. (A) Spleen cells from mice after 71 h of infection were assayed for NK cytotox-
icity against 51Cr-labeled YAC-1 target cells. (B) IFN-g levels in sera collected at 35, 45, and 71 h of MCMV infection were determined by ELISA. (C)
Expression of IFN-g mRNA in the spleens of infected mice after 71 h of MCMV injection was determined by Northern blot hybridization using 32P-
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of IRAK, NF-kB activation can still occur, possibly medi-
ated by other related kinases such as IRAK2. The relative
role of IRAK and IRAK2 in inducing JNK and NF-kB
downstream of MyD88 is still unclear and the involvement
of IRAK2 in IL-18 signaling remains to be elucidated.
Defect in IL-18–mediated Functions in the Absence of IRAK.
IL-18 alone does not support Th1 differentiation, but it can
potentiate Th1 development driven by IL-12 (4). In differ-
entiated Th1 cells, IFN-g production can be induced by
IL-18 or IL-12 alone, and this effect can be further syner-
gized by a combination of both cytokines (4). We observed
no defect in Th1 differentiation of IRAK-deficient cells
mediated by IL-12, confirming that IL-18 signaling does
not play an essential role in Th1 development. IL-18–induced
IFN-g expression in IRAK-deficient Th1 cells is signifi-
cantly decreased, although NF-kB activation is only par-
tially impaired. Increase in serum IFN-g levels as a result
of a Th1 response to P. acnes and LPS treatment, or an NK
response in the early phase of MCMV infection, was also
reduced significantly in IRAK-deficient mice. The results
suggest that optimal gene induction by IL-18 requires
proper activation of multiple signaling pathways including
NF-kB and JNK. Dramatic decrease in IFN-g production
in IRAK-deficient cells may have resulted from the impair-
ment in JNK activation even though NF-kB activity was
not severely affected. We also observed similar phenomena
in our previous studies; IL-6 induction in IRAK-deficient
fibroblasts in response to IL-1 treatment was significantly
reduced due to defects in JNK/p38 activation despite min-
imal impacts on NF-kB activation (25). The involvement
of both JNK and NF-kB pathways may imply that optimal
gene expression depends on the binding of multiple tran-
scription factors including NF-kB and AP-1 onto the pro-
moter regions of the target genes. It is also possible that the
transactivation potential of NF-kB is modulated by the ki-
nase activity of JNK and the other MAP-related kinase
p38, as suggested in studies of TNF-induced IL-6 gene ex-
pression (43).
IL-18 and IL-12 share many biological properties, although
different signaling pathways are used by the two cytokines.
Transcription factor STAT4 is activated by IL-12 whereas
NF-kB and AP-1 are activated by IL-18. The binding sites
of these transcription factors within the IFN-g promoter
region have been identified (44). IL-18 alone can directly
induce IFN-g promoter activity via AP-1, whereas IL-12–
mediated induction of the promoter activity requires both
AP-1 and STAT4 (44). Synergistic expression of IFN-g by
IL-18 and IL-12 probably results from the interplay of mul-
tiple transcription factors in differential regulation of IFN-g
promoter activity. A strong synergistic effect in IFN-g in-
duction and cell proliferation was observed in IRAK-defi-
cient Th1 cells when treated with combination of IL-12 and
IL-18. The results suggest that minimal activation of NF-kB
and JNK by IL-18 in IRAK-deficient cells is sufficient to
function synergistically with IL-12 to achieve a significant
synergistic response.
MCMV Infection in IRAK-deficient Mice. MCMV infec-
tion in mice results in a strong NK response in the early phase
of infection before the onset of T and B cell responses (34).
Induction of NK cell IFN-g production and cytotoxicity
peaks on day 2–5 of infection (34, 45). IFN-g production
by NK cells is the major defense mechanism in controlling
MCMV replication (34). It has been well characterized that
in MCMV infection IL-12 plays a major role in NK cell
IFN-g production, whereas induction of NK cytotoxicity
is regulated by IFN-a/b (35, 46). Although IL-18 is known
to be involved in NK cell function, the role of IL-18 in
NK responses during MCMV infection has not been inves-
tigated. We have undertaken this study to understand the
importance of IRAK in IL-18–mediated responses in a viral
infection. MCMV-infected IRAK-deficient mice have a
normal induction of IL-18 expression but exhibited a sig-
nificant decrease in IFN-g induction and in serum IFN-g.
The results in this study suggest that IL-18 plays a distinct
role in IFN-g production during the NK response to
MCMV infection and that its function cannot be overcome
completely by IL-12 or other mechanisms. However, we
cannot rule out the possibility that IRAK may also play a
role in viral infections via its involvement in other related
receptors in addition to the IL-18 receptor. Although we
have demonstrated a defect in IL-18–induced NK cytotox-
icity in IRAK-deficient mice, MCMV infection or poly(I):
poly(C) injection triggers a normal NK cytotoxicity in these
mice. Our results suggest that the role of IL-18 in NK cyto-
toxicity can be compensated by IFN-a/b or other mecha-
nisms during MCMV infection. Studies are underway in
our laboratory to understand the mechanisms of MCMV-
induced immune responses in IRAK-deficient mice.
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